T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial
This study not only demonstrated that early induction of nivolumab as a later-line regimen is an alternative strategy but also identified clinically available predictors for PD-1 blockade therapy.
Authors
- Mototsugu Shimokawa (ORCID: https://orcid.org/0000-0001-8140-4565)
- Hiroshi Saeki (ORCID: https://orcid.org/0000-0001-7243-6960)
- Akitaka Makiyama
- Tomomi Kashiwada (ORCID: https://orcid.org/0000-0001-8076-5545)
- Hiroo Katsuya (ORCID: https://orcid.org/0000-0003-1498-4357)
- Qingjiang Hu (ORCID: https://orcid.org/0000-0002-8313-5861)
- Atsujiro Nishioka
- Eiji Oki (ORCID: https://orcid.org/0000-0002-9763-9366)
- Itaru Yasufuku (ORCID: https://orcid.org/0000-0001-5245-7502)
- T. Nagasaka
- Hideo Baba
- Satoshi Otsu
- Yudai Shinohara
Institutions
- Gunma University (JP)
- Yamaguchi University (JP)
- Saga University (JP)
- Oita University (JP)
- Kawasaki Medical School (JP)
- Kyushu University Hospital (JP)
- Saga-Ken Medical Centre Koseikan (JP)
- Gifu University Hospital (JP)
- Kyushu Hospital (JP)
- Japan Community Healthcare Organization (JP)
- Innovative Research (United States) (US)
- Gifu University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100148
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00